Delving into the Latest Updates on Mepivacaine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+-)-1-Methyl-2',6'-pipecoloxylidide, 1-methyl-2',6'-pipecoloxylidide, DL-Mepivacaine

+ [23]

Target

VGSCs

Mechanism

Voltage-gated sodium channels blockers

Therapeutic Areas

Other Diseases

Active Indication

Anesthesia

Inactive Indication

Brachial Plexus NeuropathiesDiabetic NeuropathiesNeuralgia, Postherpetic

Originator Organization-

Active Organization

Septodont Holding SASNippon Shika Yakuhin Co. Ltd.NISSIN Pharmaceutical Co., Ltd.

+ [2]

Inactive Organization

Relmada Therapeutics, Inc.

Shandong Bestcomm Pharmaceutical Co., Ltd.

Eastman Kodak Co.

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1956),

Anesthesia

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC15H23ClN2O

InChIKeyRETIMRUQNCDCQB-UHFFFAOYSA-N

CAS Registry1722-62-9

View All Structures (2)

Persistent postoperative pain is a substantial pain (scores 4-10 using a 0-10 numeric scale) that develops 3 months after surgery.
Persistent postoperative pain can be a problem even in ambulatory surgery. Loco-regional analgesia could prevent the occurrence of this pathology but contradictory results are found in ancient studies.
This study is the first randomized controlled study in children about loco-regional analgesia and persistent postoperative pain in traumatologic orthopedic surgery.
One interventional arm will receive a locoregional analgesia after general anesthesia and before incision. The other arm will only receive systemic analgesia during general anesthesia.
The incidence of persistent postoperative pain at 3, 6 and 12 months will be compared in these two groups.
The goal is to show the decrease of the incidence of the persistent postoperative pain in the group "locoregional analgesia".

Start Date06 Jun 2024

Sponsor / Collaborator

Nantes University Hospital

[+1]

NCT05425979 / Enrolling by invitationPhase 4IIT

Onset of Sensory Blockade in Ultrasound-Guided Ankle Block with Mepivacaine Versus Bupivacaine: a Randomized Non-Inferiority Clinical Trial

The purpose of this research is to determine if both local anesthetics (mepivacaine and bupivacaine) are similar in their onset of sensory block to assess the efficiency of ultrasound-guided ankle blocks in our practice. Currently it is the standard of care to perform ankles blocks with both mepivacaine and bupivacaine. However, given similarity in their safety profile researchers would like to compare if one is non-inferior to the other in terms of onset time of ankle block.

Start Date11 Mar 2024

Sponsor / Collaborator

Mayo Clinic

NCT06291727 / RecruitingPhase 4IIT

Mepivacaine Versus Bupivacaine Spinal Anesthesia for Same Day Discharge Following Total Knee Arthroplasty

This study is a prospective, double-blind prospective randomized controlled trial comparing mepivacaine and bupivacaine spinal anesthesia for same-day discharge readiness following a unilateral primary elective TKA procedure.
Study data will be collected during the patient's hospital stay for their TKA procedure, and the primary outcome of same-day discharge readiness will be assessed the day of surgery. Patients will also be contacted at Day 3 post-op to assess for any complications, current level of pain, and pain medication utilization.

Start Date16 Feb 2024

Sponsor / Collaborator

Prisma Health

100 Clinical Results associated with Mepivacaine Hydrochloride

Login to view more data

100 Translational Medicine associated with Mepivacaine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Mepivacaine Hydrochloride

Login to view more data

2,064

Literatures (Medical) associated with Mepivacaine Hydrochloride

09 Nov 2024·Cureus

Articaine Versus Mepivacaine in Inferior Alveolar Nerve Block for Patients With Irreversible Pulpitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Review

Author: Alkandari, Meshari ; Alshammari, Talal ; Alshammari, Mohammad ; Ghaleb, Amnah ; Alenezi, Rawabi ; Almutairi, Shaikha

Inferior alveolar nerve block (IANB) as an anesthetic strategy has shown conflicting results in terms of efficacy in the treatment of patients with irreversible pulpitis. Mepivacaine and articaine are anesthetic agents commonly used in the IANB technique for pulpal anesthesia. This review aimed to compare mepivacaine and articaine regarding pain and success rate. We conducted a search on the databases PubMed, Scopus, Web of Science (WOS), and Cochrane Central for randomized controlled trials (RCTs) assessing mepivacaine versus articaine until September 2024. The primary outcome of interest was success rate, while the secondary outcomes were pain intensity assessed by a 10-point visual analog scale (VAS) and incidence of severe pain. Data were pooled as odds ratio (OR) or mean difference (MD) with 95% confidence interval (CI) in a random-effect model using STATA. Five RCTs including 568 patients were included in the final analysis. While there was no significant difference between the two studied groups regarding the success rate (OR: 0.92, 95% CI: 0.69 to 1.21, p=0.54), articaine significantly reduced the pain intensity compared to mepivacaine (MD: 0.59, 95% CI: 0.31 to 0.86], p<0.001). Moreover, no significant difference was observed regarding the incidence of severe pain. Articaine reduced the intensity of pain post-procedure, with comparable results regarding success rate and incidence of severe pain with mepivacaine. Further large-volume RCTs are warranted to study the differences between the two options in the long term.

05 Nov 2024·Schweiz Arch Tierheilkd

Sub-Tenon’s anesthesia in equine cataract surgery and vitrectomy: a retrospective case series (2018–2022)

Article

Author: Torgerson, P ; Kiesse, O ; Pot, S A ; Stadler, S

INTRODUCTIONA retrospective data analysis was performed on 17 eyes from 13 horses which underwent a sub-Tenon's injection to facilitate phacoemulsification or pars plana vitrectomy under general anesthesia between 2018 and 2022. All procedures were performed by the same veterinary ophthalmologist. Seven eyes received a sub-Tenon's dose of 7 ml lidocaine (XylocainÒ, 2 % lidocaine hydrochloride, Germany, Aspen Germany GmbH), and 10 eyes received 7 ml mepivacaine (MepinaestÒ purum 2 %, mepivacaine hydrochloride, Switzerland, Gebro Pharma GmbH). Statistical analysis compared onset and duration of globe centralization and pupil mydriasis between the two groups. Intraoperative and postoperative complications were also assessed. Mepivacaine had a significantly later onset of action regarding globe centration and mydriasis (8,9 minutes vs. 6 minutes), but also a significantly longer duration of globe centration than lidocaine (31,5 minutes vs. 15,6 minutes). There were no statistically relevant differences between solutions regarding duration of pupil dilation (40,4 minutes for 2 % lidocaine vs. 69,2 minutes for 2 % mepivacaine). Chemosis occurred in all 17 eyes. Surgical complications included corneal epithelial defects (5), retinal detachment (5), lens opacification (5), temporary blindness during recovery (3) and glaucoma (2). Sub-Tenon's anesthesia is a feasible alternative to systemic neuromuscular blockade and retrobulbar block anesthesia for surgical procedures on the equine globe. A controlled prospective in vivo study is needed to further evaluate effects and risks.

01 Nov 2024·American Journal of Obstetrics and Gynecology

Mepivacaine instillation for pain reduction during intrauterine device placement in nulliparous women: a double-blinded randomized trial

Article

Author: Envall, Niklas ; Kopp Kallner, Helena ; Elgemark, Karin

BACKGROUNDFear of pain associated with intrauterine device (IUD) placement has been identified as a significant barrier to the adoption of long-acting reversible contraception, contributing to lower utilization of the most effective reversible contraceptive methods.OBJECTIVETo assess whether instillation of intrauterine mepivacaine before IUD placement alleviates pain more effectively than a placebo.STUDY DESIGNWe conducted a multicenter, double-blind, randomized, placebo-controlled trial involving nulliparous women undergoing IUD placement. An intrauterine instillation of 10 mL of 20 mg/mL mepivacaine or 0.9 mg/mL sodium chloride was administrated through a hydrosonography catheter 2 minutes prior to IUD placement. Pain scores were assessed using a 100 mm visual analog scale (VAS) at prespecified time points. Primary outcome measured the difference in VAS pain scores between the intervention group and the placebo group during IUD placement. Secondary outcomes included VAS pain scores at instillation and 10 minutes after placement, tolerability of the placement pain, as well as acceptability of the analgesia method.RESULTSWe enrolled 151 participants, with 76 assigned to the mepivacaine group and 75 to the placebo group. The mean VAS pain score during IUD placement showed a difference of 13.3 mm (95% confidence interval (CI) 5.75-20.87; P<.001): the mepivacaine group had a mean of 53.9 mm (standard deviation [SD] 22.8), while the placebo group had a mean of 67.2 mm (SD 22.4). After adjusting for each individual provider's impact, the difference in mean pain scores remained statistically significant (12.2 mm 95% CI 4.85-19.62; P<.001). A greater proportion of women in the intervention group reported tolerable pain during placement with 70/75 participants (93.3%) compared to 53/66 participants (80.3%) in the placebo group (P=.021).CONCLUSIONThe intrauterine instillation of mepivacaine results in statistically significant reduction in pain score among nulliparous women during IUD placement. Although the precise clinical impact of this pain reduction method remains uncertain, the observed reduction in pain score result in a higher proportion of women reporting tolerable pain. This finding and the high acceptance as a pain reduction method thereby suggests clinical relevance. Intrauterine instillation of mepivacaine is a possible strategy to increase IUD utilization, particularly among nulliparous women who are at high risk of unintended pregnancy.

100 Deals associated with Mepivacaine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00738	Mepivacaine Hydrochloride	N01BB03	DB00961

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	-	-	01 Jan 1956

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anesthesia	Phase 3	US	Eastman Kodak Co.	06 Jan 1960
Brachial Plexus Neuropathies	Phase 3	CN	Shandong Bestcomm Pharmaceutical Co., Ltd.	-
Diabetic Neuropathies	Phase 3	US	Relmada Therapeutics, Inc.	-
Neuralgia, Postherpetic	Phase 3	US	Relmada Therapeutics, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03838874 (CTgov)	Phase 2/3	Osteoarthritis, Hip \| Osteoarthritis, Knee	154	Low-Dose Bupivacaine (Low-Dose Bupivacaine)	btmmzzjdhn(qmuytbfhwh) = jxnrzastki batklkmcbi (fexbviplda, myfacrqvxi - zheravebry) View more	-	12 Aug 2021
				Mepivacaine (Mepivacaine)	btmmzzjdhn(qmuytbfhwh) = pyakvhsszl batklkmcbi (fexbviplda, woyjvcbdbd - rakzhdfjqc) View more
NCT03948386 (CTgov)	Phase 4	Osteoarthritis, Hip	159	isobaric bupivacaine (Isobaric Bupivacaine)	asavjmfxyx(eomkdwrxmg) = tczabzbuhd vbtyjitbsh (rsegpgvxdj, lsxrlhwmyc - arelvcymbv) View more	-	07 May 2021
				hyperbaric bupivacaine (Hyperbaric Bupivacaine)	asavjmfxyx(eomkdwrxmg) = lhxkwymyju vbtyjitbsh (rsegpgvxdj, ubfrlcloum - syebluevlc) View more
NCT03063255 (CTgov)	Phase 4	Spasm \| Bladder Cancer	60	Obturator block (Obturator Block)	yrtpnivuuv(labmkqaxrd) = buoixtvgzl ttqxomuwjv (jfenxffzql, hdhpslrhzk - thbshoebdr) View more	-	24 Mar 2021
				Neuromuscular block (Neuromuscular Block)	yrtpnivuuv(labmkqaxrd) = orqclnvxax ttqxomuwjv (jfenxffzql, riwjyfpxqk - ewadwyzaxz) View more
NCT01574807 (CTgov)	Phase 4	Pain	100	Mepivacaine+Lidocaine (Mepivacaine + Lidocaine)	xkiesnauji(zmbcilxgej) = cwwhyajwkc jfklxdiehy (vntubrmxpx, dlayzqefrq - lnrapycduu)	-	17 Nov 2020
				Lidocaine (Lidocaine + Lidocaine)	xkiesnauji(zmbcilxgej) = uzobsoxjvi jfklxdiehy (vntubrmxpx, pvprqmgtfl - swnxsjukrn)
NCT02584452 (CTgov)	Not Applicable	Pain, Postoperative \| Anterior Cruciate Ligament Injuries	59	adductor canal continuous nerve catheter+Propofol+Mepivacaine+Fentanyl (Continuous Adductor Canal Nerve Catheter)	mpnnzzltqs(jmduczjvwz) = grwhriooeh kirraudpsf (bwvacfydhz, uwfqyqiwar - xakuccdzcf) View more	-	18 Nov 2019
				adductor canal nerve block+ropivacaine+Propofol+Mepivacaine+Fentanyl+dexamethasone (Long Acting Single Bolus Adductor Canal Nerve Block)	mpnnzzltqs(jmduczjvwz) = tporbkgnue kirraudpsf (bwvacfydhz, oglmtnjyaa - svlkiahcfj) View more
NCT03390426 (CTgov)	Phase 4	Intraoperative hypertension	31	Perifemoral Injection of Local Anesthetic+Mepivacaine (Mepivacaine Block Group)	lnjdeyqhvj(hofnbnmcsy) = kraohqogby gfmbzsoqfx (uyuqqivzaj, sibsrrqruq - stjpnkdfie) View more	-	30 Oct 2019
				Perifemoral Injection of Local Anesthetic+Saline (Saline Sham Group)	lnjdeyqhvj(hofnbnmcsy) = euihcpzrgx gfmbzsoqfx (uyuqqivzaj, fzeytcvhac - yzdcleycoq) View more
NCT02078063 (Pubmed \| Contraception)	Phase 3	Pain, Postoperative	86	Mepivacaine 1% 10mL	(qtvhvdmeqv) = blcbxbmtnw yfnsvamwgx (lerkzbhduh, 3.1 - 5.8)	-	01 Jun 2019
				0.9% NaCl	(qtvhvdmeqv) = xsqqqlhsie yfnsvamwgx (lerkzbhduh, 3.3 - 7.5)
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	etmgimypgm(bhupkjpjub) = rbpwjcaeki dnaojnwctj (nbfeqchatp, qpybjnqghy - wcfydudrrn) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	etmgimypgm(bhupkjpjub) = onproarric dnaojnwctj (nbfeqchatp, xnvhjvfgkl - dzogpflmpp) View more
AUA2018	Not Applicable	Urinary Bladder Diseases	277	mepivacaine	khwdomnuqr(dodymijnho) = mkijgzywnk lsejruqgvp (albcpvoget )	-	01 Apr 2018
NCT00825786 (CTgov)	Phase 3	-	103	Ropivacaine+Mepivacaine (Group 1)	hipjvgykpq(ispwmuiszl) = zuurdieiqu iscwhfrvxv (mdpcnwxpqh, gypwscqcvv - fjsdvsyfnc) View more	-	19 Apr 2017
				Ropivacaine+Mepivacaine (Group 2)	hipjvgykpq(ispwmuiszl) = eonbhfpdzk iscwhfrvxv (mdpcnwxpqh, mhjyoaiqhb - edekkkndrc) View more